Literature DB >> 34916685

[Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement].

L Luo1,2, X Y Xing2, Y S Xiao3, K Y Chen2, F Y Zhu2, X W Zhang2, Y H Li2.   

Abstract

OBJECTIVE: To investigate the clinical and immunological features of cardiac involvement in patients with anti-synthetase syndrome (ASS).
METHODS: In the study, 96 patients diagnosed with ASS hospitalized in the Department of Rheumatology and Immunology, Peking University People's Hospital from April 2003 to November 2020 were included. The patients were divided into two groups according to whether they were accompanied with cardiac involvement. Demographic features, clinical characteristics (Gottron's sign/papules, muscle damage, etc.), comorbidities, laboratory indices (creatine kinase, inflammatory indicators, immunoglobulin, complement, lymphocyte subset, autoantibodies, etc.) were collected and the differences between the two groups were analyzed statistically.
RESULTS: The prevalence of cardiac involvement in the patients with ASS was 25.0% (24/96). The ASS patients complicated with cardiac involvement presented with elevated cardiac troponin I (cTnI, 75.0%, 18/24), pericardial effusion (33.3%, 8/24), reduction of left ventricular function (33.3%, 8/24) and valves regurgitation (33.3%, 8/24). The age of onset of the patients with cardiac involvement was older than that of the patients without cardiac involvement [(54.58±10.58) years vs. (48.47±13.22) years, P=0.043). Arthritis was observed less frequently in the patients with cardiac involvement than those without cardiac involvement (37.5% vs. 61.1%, P=0.044). In addition, rapidly progressive interstitial lung disease (54.2% vs. 30.6%, P=0.037) was observed more frequently in the patients with cardiac involvement than those without cardiac involvement. As compared with the ASS patients without cardiac involvement, C-reactive protein (CRP) [(13.55 (8.96, 38.35) mg/L vs. 4.60 (1.37, 17.40) mg/L, P=0.001], and lactate dehydrogenase (LDH) [408.0 (255.0, 587.0) U/L vs. 259.5 (189.8, 393.8) U/L, P=0.007] were significantly higher in the patients with cardiac involvement. Anti-Ro-52 antibody was detected more commonly in the ASS patients with cardiac involvement compared with the patients without cardiac involvement (91.7% vs. 69.4%, P=0.029). No significant differences were found in the comorbidities, alanine transaminase (ALT), aspartate transaminase (AST), creatine kinase (CK), erythrocyte sedimentation rate (ESR), ferritin (Fer), immunoglobulin G (IgG), complement 3 (C3), complement 4 (C4), lymphocyte subset between the two groups.
CONCLUSION: Cardiac involvement is common in ASS, mainly manifested as myocardial damage. It is necessary to be aware of cardiac complications in patients with elevated CRP, elevated LDH and positive anti-Ro-52 antibody.

Entities:  

Keywords:  Anti-synthetase syndrome; Autoantibodies; Myocarditis; Myositis

Mesh:

Substances:

Year:  2021        PMID: 34916685      PMCID: PMC8695161     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  14 in total

1.  Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.

Authors:  Isabelle Marie; Pierre Yves Hatron; Stéphane Dominique; Patrick Cherin; Luc Mouthon; Jean-François Menard; Hervé Levesque; Fabienne Jouen
Journal:  Semin Arthritis Rheum       Date:  2011-11-09       Impact factor: 5.532

2.  Severe aortic regurgitation secondary to antisynthetase syndrome.

Authors:  Kerunne S Ketlogetswe; Joseph Aoki; Thomas A Traill; Oscar H Cingolani
Journal:  Circulation       Date:  2011-07-19       Impact factor: 29.690

Review 3.  Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.

Authors:  Ane Labirua-Iturburu; Albert Selva-O'Callaghan; Melinda Vincze; Katalin Dankó; Jiri Vencovsky; Benjamin Fisher; Peter Charles; Maryam Dastmalchi; Ingrid E Lundberg
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

4.  In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease.

Authors:  R La Corte; A Lo Mo Naco; A Locaputo; F Dolzani; F Trotta
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

Review 5.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

6.  Brief report: antisynthetase syndrome-associated myocarditis.

Authors:  Kavita Sharma; Ana-Maria Orbai; Dipan Desai; Oscar H Cingolani; Marc K Halushka; Lisa Christopher-Stine; Andrew L Mammen; Katherine C Wu; Sammy Zakaria
Journal:  J Card Fail       Date:  2014-07-29       Impact factor: 5.712

Review 7.  Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies?

Authors:  Aleksandra Halina Opinc; Marcin Adam Makowski; Zuzanna Małgorzata Łukasik; Joanna Samanta Makowska
Journal:  Heart Fail Rev       Date:  2019-12-23       Impact factor: 4.214

8.  Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes.

Authors:  Céline Dieval; Christophe Deligny; Alain Meyer; Philippe Cluzel; Nicolas Champtiaux; Guillaume Lefevre; David Saadoun; Jean Sibilia; Jean-Luc Pellegrin; Eric Hachulla; Olivier Benveniste; Baptiste Hervier
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Authors:  James B Lilleker; Jiri Vencovsky; Guochun Wang; Lucy R Wedderburn; Louise Pyndt Diederichsen; Jens Schmidt; Paula Oakley; Olivier Benveniste; Maria Giovanna Danieli; Katalin Danko; Nguyen Thi Phuong Thuy; Monica Vazquez-Del Mercado; Helena Andersson; Boel De Paepe; Jan L deBleecker; Britta Maurer; Liza J McCann; Nicolo Pipitone; Neil McHugh; Zoe E Betteridge; Paul New; Robert G Cooper; William E Ollier; Janine A Lamb; Niels Steen Krogh; Ingrid E Lundberg; Hector Chinoy
Journal:  Ann Rheum Dis       Date:  2017-08-30       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.